Peter Drueckes

Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.

Eric Vangrevelinghe, Clive McCarthy, Pascal Furet, 2010, Bioorganic & medicinal chemistry letters.

A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.

Joseph Schoepfer, Clive McCarthy, Pascal Furet, 2011, Cancer research.

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.

Pascal Furet, C. Schnell, J. Brueggen, 2011, Journal of medicinal chemistry.

A Fluorescence Lifetime-Based Assay for Abelson Kinase

Lorenz M. Mayr, U. Hassiepen, L. Mayr, 2011, Journal of biomolecular screening.

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

Audrey Kauffmann, Jianjun Yu, Yumin Dai, 2014, Clinical Cancer Research.

2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.

Eric Vangrevelinghe, Marc Lang, Pascal Furet, 2010, Bioorganic & medicinal chemistry letters.